ArticleJournal of hepatocellular carcinoma2024
A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Advancing risk stratification in intermediate-stage hepatocellular carcinoma undergoing transarterial chemoembolization: the promise of the NTAA model.Hepatobiliary surgery and nutrition · 2026Article
- Unlocking the potential of radiomics in predicting the response of neoadjuvant immunochemotherapy for operable locally advanced esophageal squamous cell carcinoma: a narrative review.Journal of thoracic disease · 2026Review
- CT-based deep learning signatures associated with transcriptomic heterogeneity and combined with nutritional biomarkers improve prediction of 3-year overall survival in esophageal squamous cell carcinoma.Insights into imaging · 2026Article
- Aflatoxin B1 Impairs TACE Efficacy Through Downregulated Carbonic Anhydrase 2: A Bioinformatics Analysis.International journal of genomics · 2026Article
- Identification and validation of prognostic genes related to glycolysis and M2 macrophage in hepatocellular carcinoma: an integrated analysis of bulk RNA sequencing and single-cell RNA sequencing.Frontiers in immunology · 2026Article
- TACE Combined with Targeted Immunotherapy: A Strategy for Liver Transplantation Conversion and Survival Benefits in Patients with BCLC Stage B/C HCC.Journal of hepatocellular carcinoma · 2026Article
- Decoding Treatment Response in Hepatocellular Carcinoma: The Era of Radiomics and Radiogenomics.Journal of hepatocellular carcinoma · 2026Review
- Artificial Intelligence Applications in Interventional Radiology.Journal of personalized medicine · 2025Review
- Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC.Cancer drug resistance (Alhambra, Calif.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The response to transarterial chemoembolization (TACE) varies among individuals with hepatocellular carcinoma (HCC). This study aimed to identify a biomarker for predicting TACE response in HCC patients and to investigate its correlations with the tumor microenvironment and pre-TACE radiomics features. Patients and Methods: GSE104580 data were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed gene analysis and machine learning algorithms were used to identify genes for constructing the TACE failure signature (TFS). TFS scores were then calculated for HCC patients in The Cancer Genome Atlas (TCGA) cohort. After obtaining images from The Cancer Imaging Archive (TCIA), tumor labeling and radiomics feature extraction, the Rad-score model was generated. Correlation analysis was performed between the TFS score and the Rad-score. CIBERSORT, ssGSEA and TME analysis were performed to explore differences in the immune landscape among distinct risk groups. The immunotherapy response was compared between different groups. Results: ADH1C, CXCL11, EMCN, SPARCL1 and LIN28B were selected and incorporated into the TFS, which demonstrated satisfactory performance in predicting TACE response. Patients in the high TFS score group had poorer overall survival (OS) than those in the low TFS score group. The Rad-score model was constructed using six radiomics features, and the Rad-score was significantly correlated with hub gene expression and the TFS score. The high-TFS group was also characterized by an immunosuppressive tumor microenvironment and exhibited unfavorable responses to immunotherapy with PD-1 and CTLA-4 checkpoint inhibitors. Conclusion: This study established a transcriptomic biomarker for predicting the efficacy of TACE that correlates with radiomics features on pretreatment imaging, tumor immune microenvironment characteristics, and the efficacy of immunotherapy and targeted therapy in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.